Dr. Reddy's Laboratories Ltd ADR(RDY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:13 AM ET (Korea 9/11 20:13)
Full metrics table
| Index | - | P/E | 26.31 | EPS (ttm) | 0.45 | Insider Own | - | Shs Outstand | 833.0M | Perf Week | -3.78% |
| Market Cap | 9.75B | Forward P/E | 19.81 | EPS next Y | 31.37% | Insider Trans | - | Shs Float | 833.0M | Perf Month | -5.94% |
| Enterprise Value | 9.69B | PEG | 1.91 | EPS next Q | 0.1 | Inst Own | 15.37% | Short Float | 2.7% | Perf Quarter | -11.95% |
| Income | 0.37B | P/S | 2.66 | EPS this Y | -16.33% | Inst Trans | -3.65% | Short Ratio | 8.15 | Perf Half Y | -19.46% |
| Sales | 3.66B | P/B | 2.41 | EPS next 5Y | 10.37% | ROA | 6.12% | Short Interest | 22.51M | Perf YTD | -16.6% |
| Book/sh | 4.86 | P/C | 11.34 | EPS past 3/5Y | -4.82% 15.78% | ROE | 9.13% | 52W High | -25.27% ($15.67) | Perf Year | -19.68% |
| Cash/sh | 1.03 | P/FCF | - | Sales past 3/5Y | 7.5% 8.27% | ROIC | 8.89% | 52W Low | 3.08% ($11.36) | Perf 3Y | -13.64% |
| Dividend Est. | $0.08 (0.69%) | EV/EBITDA | - | EPS Y/Y TTM | -44.35% | Gross Margin | 54.19% | Volatility(W/M) | 1.42% 1.34% | Perf 5Y | -11.22% |
| Dividend TTM | 0.08 | EV/Sales | 2.65 | Sales Y/Y TTM | -6.76% | Oper. Margin | 10.08% | ATR (14) | 0.21 | Perf 10Y | 25.08% |
| Dividend Ex-Date | 2026/7/24 | Quick Ratio | 1.39 | EPS Q/Q | -71.69% | Profit Margin | 10.14% | RSI (14) | 31.01 | Recom | 2.8 |
| Dividend Gr. 3/5Y | -9.14% - | Current Ratio | 1.9 | Sales Q/Q | -14.64% | SMA20 | -3.39% ($12.12) | Beta | 0.3 | Target Price | $13.08 |
| Payout | 11.04% | Debt/Eq | 0.19 | Earnings | 2026/7/21 | SMA50 | -5.78% ($12.43) | Rel Volume | 0.93 | Prev Close | $11.88 |
| Employees | - | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -39.87% -1.75% | SMA200 | -12.8% ($13.43) | Avg Volume(3M) | 2.76M | Price | $11.71 |
| IPO | 2001/4/11 | Option/Short | Yes/Yes | Trades | 8524 | Volume | 2,579,983 | Change | -1.43% |
Company
RDY is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
An Indian pharmaceutical company that develops and manufactures generic drugs, active pharmaceutical ingredients (APIs), and biosimilars, supplying them to the United States, India, and emerging markets. It is a global generic and specialty pharmaceutical company listed on the US stock exchange as an ADR.
Over the past 1 year, on the lower side
25% below its 1-year high.
RDY makes money exceptionally well
10.08% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -16.3% this year.
Tap to view numbers
The price looks about right
Trading at 26.3 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -13.6% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 0.69% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 15.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
INDQ 0.05%
IMVP 0.03%
EDOG 0.03%
EMOP 0.03%
NFTY 0.02%It ranks #4 in the industry
Based on market cap of $10B.
RDY $10B PER 26.3
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is RDY?
RDY belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of RDY?
The market cap of RDY is approximately $9.8B, ranking 953 within its sector.
Does RDY pay dividends?
RDY has a dividend yield of approximately 0.69%, with an annual dividend of $0.08.
What is the P/E ratio of RDY?
RDY has a P/E ratio of approximately 26.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for RDY?
RDY has recorded a 52-week high of $15.67 and a low of $11.36.
